(Q37337123)

19 August 2017

Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies (English)

1 reference

19 August 2017

0 references

12

1 reference

19 August 2017

Shivaani Kummar

1

1 reference

19 August 2017

Robert Kinders

2

1 reference

19 August 2017

Martin E Gutierrez

3

1 reference

19 August 2017

Larry Rubinstein

4

1 reference

19 August 2017

Ralph E Parchment

5

1 reference

19 August 2017

Lawrence R Phillips

6

1 reference

19 August 2017

Jiuping Ji

7

1 reference

19 August 2017

Anne Monks

8

1 reference

19 August 2017

Jennifer A Low

9

1 reference

19 August 2017

Alice Chen

10

1 reference

19 August 2017

Anthony J Murgo

11

1 reference

19 August 2017

Seth M Steinberg

13

1 reference

19 August 2017

Helen Eliopoulos

14

1 reference

19 August 2017

Vincent L Giranda

15

1 reference

19 August 2017

Gary Gordon

16

1 reference

19 August 2017

Lee Helman

17

1 reference

19 August 2017

Robert Wiltrout

18

1 reference

19 August 2017

Joseph E Tomaszewski

19

1 reference

19 August 2017

James H Doroshow

20

1 reference

19 August 2017

language of work or name

English

0 references

publication date

13 April 2009

1 reference

Journal of Clinical Oncology

19 August 2017

1 reference

19 August 2017

27

1 reference

19 August 2017

2705-2711

1 reference

19 August 2017

16

1 reference

Liquid Chromatographic Determination of NSC 737664 (ABT-888: an Inhibitor of Poly(ADP-ribose) Polymerase (PARP)) in Plasma and Urine in a Phase 0 Clinical Trial

19 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2739635

Preclinical modeling of a phase 0 clinical trial: qualification of a pharmacodynamic assay of poly (ADP-ribose) polymerase in tumor biopsies of mouse xenografts

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2739635

Designing phase 0 cancer clinical trials

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2739635

Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2739635

Current development of clinical inhibitors of poly(ADP-ribose) polymerase in oncology

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2739635

Poly(ADP-ribose): novel functions for an old molecule

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2739635

Inhibition of poly(ADP-ribose) polymerase in cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2739635

Chemopotentiation by PARP inhibitors in cancer therapy.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2739635

Poly(ADP-ribose) polymerase and the therapeutic effects of its inhibitors

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2739635

Can the pharmaceutical industry reduce attrition rates?

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2739635

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2739635

Regulation of Chromatin Structure and Gene Activity by Poly(ADP-Ribose) Polymerases

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2739635

Requirement of poly(ADP-ribose) polymerase in recovery from DNA damage in mice and in cells

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2739635

New targets for cancer chemotherapy--poly(ADP-ribosylation) processing and polyisoprene metabolism

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2739635

Enhanced expression of poly(ADP-ribose) synthetase gene in malignant lymphoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2739635

Inhibition of poly(ADP-ribose) polymerase enhances cell death and improves tumor growth delay in irradiated lung cancer models

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2739635

ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2739635

The response of Parp knockout mice against DNA damaging agents.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2739635

Patient perspectives on phase 0 clinical trials

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2739635

Compressing drug development timelines in oncology using phase '0' trials.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2739635

Sequential tumor biopsies in early phase clinical trials of anticancer agents for pharmacodynamic evaluation.

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2739635

Are we taking without giving in return? The ethics of research-related biopsies and the benefits of clinical trial participation

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2739635

Enhanced polyadenosine diphosphate-ribosylation in cirrhotic liver and carcinoma tissues in patients with hepatocellular carcinoma

20 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/19364967

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1200/JCO.2008.19.7681

1 reference

19 August 2017

1 reference

19 August 2017

1 reference